Researchers Have Produced Important Chiral Multi-centered Fused Tricyclic Compounds
Representative examples of bioactive molecules having hydronaphthofurans scaffolds. Credit: Osaka University
Researchers have developed a highly efficient way to produce chiral multi-centered fused tricyclic compounds of which core structure is often found in bioactive compounds including medicines.
Chemists have devoted tremendous efforts to develop a way to build molecules as they want. A single enantiomer (specific special arrangement of atoms) is essential for molecules of specific biomedical properties because of chiral nature of biological receptor sites (usually proteins). A very challenging goal in organic chemistry is asymmetric synthesis, selective preparation of a single enantiomer of a molecule.
Recently, chemists at Osaka University has synthesized highly enantioselective polycyclic chiral compounds with multiple chiral centers in an elegant and selective manner that could open new avenues in research and industry.
In their report in Nature Communications, the Osaka team focused to develop a novel and practical way to synthesize tricyclic molecules, named hydronaphthofurans. These scaffolds are abundant in natural products of important biological activities. The representative members of this family are morphine, azadirachtin, teucvidin and momilacton that are well-known to show a range of biological activities such as analgesic, anti-tumor, insecticides, and allelochemicals. Although some are found in nature, preparing them in the synthetic laboratory with the complete control of selectivity is a major challenge to the synthetic chemists.
A reported synthesis by a Spanish group used an organic molecule based chiral catalyst to produce a tricyclic scaffold with three chiral centers. On the other hand, the Osaka team adopted a conceptually different strategy to build the tricyclic scaffold with five chiral centers (Scheme 1). Starting with a cheap raw material with just one ring (phenols), they used an organometallic nickel-based chiral catalyst to construct further two rings through a reaction termed oxidative cyclization (1 to 2). In situ displacement of nickel from an intermediate 2 with another reactive molecule of desired substituents afforded a variety of hydronaphthofurans. The final product is formed as single isomer and that contained at least five chiral centers, distributed among all three rings.
Ravindra Kumar, a one of the team member explains, "The catalyst is key to chiral selectivity, since it is chiral itself." In fact, although the application of nickel catalysts are widespread in organic synthesis, none had used in this reaction before. "In an organometallic catalyst, it's crucial to attach a suitable ligand [organic molecule, L*] to the metal atom to determine the reaction outcome. The ligand is typically a bulky organic molecule with multiple ring systems. In our case, it was a process of informed trial-and-error to find a suitable ligand that gave the desired product as a single compound (out of possible sixteen) both in high yield and with excellent chiral purity.
With the suitable catalyst in hand, the team successfully produced over twenty compounds in good yields and with 94 to 99% enantioselectivity of all five chiral centers -- a spectacle achievement! Tolerance of a wide range of substituents (R) (halogens, benzene rings and esters) in the developed method and presence of functionalizable group (carbonyls and olefins) expand the potential synthetic utility of tricyclic products to bioactive molecules after functional group transformation. Apart from offering excellent chiral purity, the reaction is also rapid and economical in terms of starting raw materials, which are crucial requirements for scaling up the research from laboratory to industrial production.
"These tricyclic products have traditionally been made by stepwise ring construction, but that tends to be slow and inefficient," Sensuke Ogoshi, the team director, says. "Our direct two-step cyclization provides access to a range of very useful scaffolds for natural products. In the long run, this could not only simplify the production of known medicines, but perhaps lead to the discovery of new compounds with medicinal or other biological properties."
This article has been republished from materials provided by Osaka University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 1 ADD COMMENT
Sorice Madina | Jan 05, 2018
Around age 60 I noticed that my handwriting was getting smaller and I was writing faster. I also noticed a small tremor in my right hand. The doctor went over my different symptoms and he suspected I'd either had a small stroke or the beginnings of Parkinson 's disease. After finding a neurologist and some testing I was diagnosed with the beginning stages of Parkinson’s disease. That was 4 years ago. I take Sinimet four times a day to control my symptoms, which include falling, imbalance, gait problems, swallowing difficulties, and slurring of speech,This year, our family doctor started me on Mbeki Herbal Clinic Parkinson’s Disease Herbal mixture, 5 weeks into treatment I improved dramatically. At the end of the full treatment course, the disease is totally under control. No case of dementia, hallucination, weakness, muscle pain or tremors. Visit Mbeki Herbal Clinic official website ww w.mbekiherbalclinic .com. I am strong again and able to go about daily activities. This Herbal Formula is Incredible!!
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018